Total Payments
$142,313
2024 Payments
$20,835
Companies
96
Transactions
1,212
Medicare Patients
6,472
Medicare Billing
$608,081
Payment Breakdown by Category
Other$86,536 (60.8%)
Food & Beverage$22,066 (15.5%)
Research$17,640 (12.4%)
Travel$11,885 (8.4%)
Consulting$3,940 (2.8%)
Education$246.14 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $77,186 | 59 | 54.2% |
| Food and Beverage | $22,066 | 1,072 | 15.5% |
| Unspecified | $17,640 | 1 | 12.4% |
| Travel and Lodging | $11,885 | 56 | 8.4% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $5,000 | 2 | 3.5% |
| Honoraria | $4,350 | 2 | 3.1% |
| Consulting Fee | $3,940 | 6 | 2.8% |
| Education | $246.14 | 14 | 0.2% |
Payments by Type
General
$124,673
1,211 transactions
Research
$17,640
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $39,292 | 94 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $22,674 | 64 | $0 (2022) |
| UCB, Inc. | $22,219 | 80 | $0 (2024) |
| Eli Lilly and Company | $17,640 | 1 | $0 (2024) |
| LivaNova USA, Inc. | $11,718 | 70 | $0 (2024) |
| SK Life Science, Inc. | $4,687 | 12 | $0 (2024) |
| AQUESTIVE THERAPEUTICS, INC. | $4,213 | 9 | $0 (2021) |
| Cyberonics, Inc. | $3,169 | 9 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $1,262 | 65 | $0 (2024) |
| Biogen, Inc. | $1,202 | 57 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,835 | 139 | Eli Lilly and Company ($17,640) |
| 2023 | $3,216 | 156 | Averitas Pharma Inc. ($239.24) |
| 2022 | $6,516 | 145 | EISAI INC. ($3,729) |
| 2021 | $4,117 | 111 | SK Life Science, Inc. ($2,214) |
| 2020 | $12,260 | 72 | Eisai Inc. ($8,697) |
| 2019 | $20,382 | 191 | EISAI INC. ($8,485) |
| 2018 | $33,863 | 199 | Eisai Inc. ($10,850) |
| 2017 | $41,124 | 199 | UCB, Inc. ($15,063) |
All Payment Transactions
1,212 individual payment records from CMS Open Payments — Page 1 of 49
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | CATALYST PHARMACEUTICALS, INC. | FIRDAPSE (Drug) | Food and Beverage | Cash or cash equivalent | $27.69 | General |
| Category: NEUROLOGY | ||||||
| 12/18/2024 | ABBVIE INC. | VYALEV (Drug) | Food and Beverage | In-kind items and services | $4.60 | General |
| Category: NEUROSCIENCE | ||||||
| 12/17/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $25.45 | General |
| Category: Neurology | ||||||
| 12/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $23.77 | General |
| Category: Neuropsychiatry | ||||||
| 12/06/2024 | LivaNova USA, Inc. | VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Neurology | ||||||
| 12/05/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Central Nervous System | ||||||
| 12/04/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.26 | General |
| Category: NEUROSCIENCE | ||||||
| 12/03/2024 | UCB, Inc. | Nayzilam (Drug) | Food and Beverage | In-kind items and services | $41.41 | General |
| Category: Neurology | ||||||
| 11/26/2024 | Biogen, Inc. | SKYCLARYS (Drug) | Food and Beverage | In-kind items and services | $28.68 | General |
| Category: Neurology | ||||||
| 11/25/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $6.81 | General |
| Category: NEUROSCIENCE | ||||||
| 11/19/2024 | Lilly USA, LLC | KISUNLA (Drug) | Food and Beverage | In-kind items and services | $20.15 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $17.78 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 11/14/2024 | ABBVIE INC. | VYALEV (Drug), DUOPA | Food and Beverage | In-kind items and services | $9.11 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | Biogen, Inc. | TYSABRI (Biological), VUMERITY | Food and Beverage | In-kind items and services | $19.87 | General |
| Category: Neurology | ||||||
| 11/12/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $24.80 | General |
| Category: Rare Disease | ||||||
| 11/12/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $1.38 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $31.15 | General |
| Category: Inflammation/Rare Disease | ||||||
| 11/06/2024 | ABBVIE INC. | VYALEV (Drug), DUOPA | Food and Beverage | In-kind items and services | $19.05 | General |
| Category: NEUROSCIENCE | ||||||
| 11/05/2024 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $29.22 | General |
| 10/30/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $30.49 | General |
| Category: NEUROLOGY | ||||||
| 10/30/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $2.34 | General |
| Category: NEUROSCIENCE | ||||||
| 10/29/2024 | Biogen, Inc. | TYSABRI (Biological) | Food and Beverage | In-kind items and services | $20.47 | General |
| Category: Neurology | ||||||
| 10/28/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $17,640.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | ||||||
| 10/17/2024 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: Neurology | ||||||
| 10/17/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $8.02 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, DOSE-FINDING STUDY EVALUATING LY3848575 IN CHRONIC NEUROPATHIC PAIN ASSOCIATED WITH DISTAL SENSORY POLYNEUROPATHY | Eli Lilly and Company | $17,640 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,370 | 2,000 | $711,318 | $140,529 |
| 2022 | 19 | 1,664 | 2,404 | $834,077 | $169,248 |
| 2021 | 18 | 1,664 | 2,271 | $766,364 | $158,501 |
| 2020 | 20 | 1,774 | 2,300 | $677,731 | $139,803 |
Total Patients
6,472
Total Services
8,975
Medicare Billing
$608,081
Procedure Codes
75
All Medicare Procedures & Services
75 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 347 | 500 | $173,500 | $39,977 | 23.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 117 | 139 | $67,415 | $15,809 | 23.4% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Office | 2023 | 99 | 264 | $72,497 | $14,900 | 20.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 204 | 231 | $56,364 | $12,305 | 21.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 80 | 80 | $47,520 | $11,270 | 23.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 82 | 82 | $36,818 | $9,301 | 25.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 16 | 64 | $24,256 | $6,302 | 26.0% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2023 | 17 | 17 | $20,230 | $5,713 | 28.2% |
| 95976 | Electronic analysis of neurostimulator generator with simple cranial nerve stimulator programming | Office | 2023 | 58 | 193 | $106,343 | $5,128 | 4.8% |
| 95816 | Measurement of brain wave activity (eeg), awake and drowsy | Office | 2023 | 17 | 17 | $16,905 | $4,748 | 28.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 41 | 47 | $16,309 | $3,101 | 19.0% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 25 | 36 | $9,792 | $2,694 | 27.5% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 78 | 94 | $18,326 | $2,508 | 13.7% |
| 95910 | Nerve conduction, 7-8 studies | Office | 2023 | 19 | 19 | $10,013 | $2,406 | 24.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 32 | 34 | $8,330 | $1,569 | 18.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 107 | 143 | $2,860 | $1,201 | 42.0% |
| 95977 | Electronic analysis of implanted neurostimulator generator with complex cranial nerve stimulator programming | Office | 2023 | 12 | 21 | $17,115 | $814.80 | 4.8% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Office | 2023 | 19 | 19 | $6,725 | $783.13 | 11.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 424 | 659 | $228,673 | $53,562 | 23.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 123 | 147 | $71,295 | $19,178 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 253 | 292 | $71,248 | $16,095 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 91 | 91 | $54,054 | $13,132 | 24.3% |
| 99309 | Follow-up nursing facility visit per day, typically 25 minutes | Office | 2022 | 117 | 276 | $68,172 | $12,967 | 19.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 71 | 71 | $31,879 | $7,974 | 25.0% |
| 95819 | Measurement of brain wave activity (eeg), awake and asleep | Office | 2022 | 19 | 19 | $22,610 | $6,254 | 27.7% |
About Dr. Robert Armstrong, MD
Dr. Robert Armstrong, MD is a Neurology healthcare provider based in Asheville, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518945617.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Armstrong, MD has received a total of $142,313 in payments from pharmaceutical and medical device companies, with $20,835 received in 2024. These payments were reported across 1,212 transactions from 96 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($77,186).
As a Medicare-enrolled provider, Armstrong has provided services to 6,472 Medicare beneficiaries, totaling 8,975 services with total Medicare billing of $608,081. Data is available for 4 years (2020–2023), covering 75 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Asheville, NC
- Active Since 01/09/2006
- Last Updated 09/21/2020
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1518945617
Products in Payments
- Fycompa (Drug) $39,166
- APTIOM (Drug) $22,736
- VNS Therapy (Device) $14,563
- Briviact (Drug) $14,438
- Vimpat (Drug) $7,378
- SYMPAZAN (Drug) $4,213
- Cenobamate (Drug) $2,305
- XCOPRI (Drug) $2,175
- Gocovri (Drug) $738.17
- TYSABRI (Biological) $629.13
- BOTOX (Biological) $588.87
- KESIMPTA (Drug) $541.34
- TROKENDI XR (Drug) $457.42
- ZEPOSIA (Drug) $444.12
- ACTHAR (Biological) $420.53
- EPIDIOLEX (Drug) $345.48
- Aimovig (Biological) $338.88
- ARZERRA (Drug) $324.44
- RYTARY (Drug) $317.44
- NUPLAZID (Drug) $308.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Asheville
James Patton, Md, MD
Neurology — Payments: $262,720
Neurology $262,720
Dr. Matthew Engelbrecht, M.d, M.D
Neurology — Payments: $51,456
Neurology $51,456
Dr. Lei Lu
Neurology — Payments: $2,910
Neurology $2,910
Alexander Schneider, M.d, M.D
Neurology — Payments: $1,133
Neurology $1,133
Anna-Marieta Moise, M.d, M.D
Neurology — Payments: $1,118
Neurology $1,118
Dr. Alendia Hartshorn, Md, MD
Neurology — Payments: $720.83
Neurology $720.83